# A Two-part Study to Compare a Tablet and Capsule Formulation of GSK2838232 With and Without Food, and to Assess the Safety and Drug Levels of Repeated Once-daily Doses of GSK2838232 Without Ritonavir

> **NCT03234036** · PHASE1 · COMPLETED · sponsor: **GlaxoSmithKline** · enrollment: 26 (actual)

## Conditions studied

- Infection, Human Immunodeficiency Virus
- HIV Infections

## Interventions

- **DRUG:** GSK2838232 100 mg tablet
- **DRUG:** GSK2838232 50 mg capsule
- **DRUG:** Ritonavir 100 mg tablets
- **DRUG:** Placebo for GSK2838232 tablets

## Key facts

- **NCT ID:** NCT03234036
- **Lead sponsor:** GlaxoSmithKline
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2017-08-02
- **Primary completion:** 2017-11-10
- **Final completion:** 2017-11-10
- **Target enrollment:** 26 (ACTUAL)
- **Last updated:** 2020-10-28


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03234036

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03234036, "A Two-part Study to Compare a Tablet and Capsule Formulation of GSK2838232 With and Without Food, and to Assess the Safety and Drug Levels of Repeated Once-daily Doses of GSK2838232 Without Ritonavir". Retrieved via AI Analytics 2026-05-31 from https://api.ai-analytics.org/clinical/NCT03234036. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*